Ontology highlight
ABSTRACT: Aim
To characterize the disease-causing mutations in a Chinese family with ectopia lentis syndrome (ELS).Methods
Patients and their family members were given complete physical, ophthalmic, and cardiovascular examinations. Genomic DNA samples were extracted from the peripheral blood of the pedigree members and 100 healthy controls. Mutation screening was performed in the fibrillin-1 (FBN1) gene by bi-directional sequencing of the amplified products. The mutation was analyzed using two bioinformatics methods.Results
A novel heterozygous c.305G>A mutation in exon 3 of FBN1 was detected. As a result of this change, a highly conserved cysteine residue was replaced by a tyrosine residue (p.C102Y). Another mutation was found in the same exon (c.303T>C), which did not change the amino acid sequence. Both mutations were discovered in each affected individual, but not in the unaffected family members, or in 100 ethnically matched controls. A bioinformatics analysis predicted that mutation p.C102Y would affect protein function.Conclusion
In the first epidermal growth factor-like module, we identified a novel FBN1 mutation (p.C102Y), which caused ELS in the family. Our study presented a unique phenotype, including some distinct ophthalmic findings, such as hypoplasia of the iris and anisometropia. Our results expanded the mutation spectrum of FBN1 and enriched the overall knowledge of genotype-phenotype correlations due to FBN1 mutations.
SUBMITTER: Zhai Y
PROVIDER: S-EPMC4631002 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
Zhai Yi Y Wang Wei W Zhu Ya-Nan YN Li Jin-Yu JY Yu Yin-Hui YH Lai Kai-Ran KR Yao Ke K
International journal of ophthalmology 20151018 5
<h4>Aim</h4>To characterize the disease-causing mutations in a Chinese family with ectopia lentis syndrome (ELS).<h4>Methods</h4>Patients and their family members were given complete physical, ophthalmic, and cardiovascular examinations. Genomic DNA samples were extracted from the peripheral blood of the pedigree members and 100 healthy controls. Mutation screening was performed in the fibrillin-1 (FBN1) gene by bi-directional sequencing of the amplified products. The mutation was analyzed using ...[more]